Bruce Eric Sands MD

Inflammatory Bowel Disease

Gastroenterology at Mount Sinai Doctors Faculty Practice

5 E 98th StFl 11New York, NY 10029
Phone+1 212-241-4299
Fax+1 212-426-5099

Dr. Sands is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sands' full profile Already have an account?

Summary

Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn's & Colitis Center at Massachusetts General Hospital in Boston, Acting Chief of the Gastrointestinal Unit, and Associate Professor of Medicine at Harvard Medical School.

A longtime advocate for the continued translational research in Crohn's disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials. Dr. Sands was also principal investigator for the landmark ACCENT II study, an international project that demonstrated the efficacy of the anti-tumor necrosis factor antibody infliximab as a long-term treatment for fistulizing Crohn's disease.

Dr. Sands' research also explores IBD epidemiology and includes the creation of OSCCAR (the Ocean State Crohn's & Colitis Area Registry), a population-based cohort of IBD in Rhode Island, a project that is funded by the Centers for Disease Control and Prevention.

A leader in several major professional organizations, Dr. Sands has served as chair of the Clinical Research Alliance of the Crohn's & Colitis Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA), and Chair of the International Organization for the Study of IBD. He is an AGA Fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG).

Education & Training

Massachusetts General HospitalCertificate, Physician Leadership, Mass General Physician Organization, 2005 - 2006
Harvard T.H. Chan School of Public HealthM.S., Epidemiology, 2001
Mass General Brigham/Massachusetts General HospitalFellowship, Gastroenterology, 1990 - 1994
Harvard T.H. Chan School of Public HealthNo degree, Clinical Effectiveness, 1993
University of Pennsylvania Health SystemResidency, Internal Medicine, 1987 - 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 2010 - 2028
MA State Medical License 1990 - 2011
PA State Medical License 1988 - 1990
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2016-2017
Selected for "Best Doctors in America" 2003-2016

Clinical Trials

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. Start of enrollment: 2013 Feb 01
COMPLETED
PHASE2
Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease
COMPLETED
Evaluating a Shared Decision Making Program for Crohn's Disease
COMPLETED
NA

Publications & Presentations

PubMed

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
Vipul Jairath, Jaroslaw Kierkuś, George Aaron Duvall, Silvio Danese, Bruce E Sands
The Lancet. Gastroenterology & Hepatology. 2026-09-01
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
Walter Reinisch, David Stepek, Radoslaw Kempinski, Silvio Danese, Bruce E Sands
The Lancet. Gastroenterology & Hepatology. 2026-09-01
Epidemiology and Treatment of Inflammatory Bowel Disease in Pregnancy: Results from a Retrospective, Observational Study.
Uma Mahadevan, Bruce E Sands, Christina Ha, Doris Yimgang, Emma Yue
Digestive Diseases and Sciences. 2026-07-01

Journal Articles

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Leah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Gursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature
Correction: ACG Clinical Guideline: Management of Crohn’s Disease in Adults
Gary R Lichtenstein, Bruce E Sands, Miguel D Regueiro, Kim L Isaacs, Nature

Books/Book Chapters

Mount Sinai Expert Guides: Gastroenterology
Sands, BEWiley Blackwell, Hoboken, NJ2015
Pocket Guide to IBD
Chapter: Foreword
Sands BEEditors: Kane SV and Dubinsky MC.SLACK, Inc., Thorofare, NJ2011
Inflammatory Bowel Disease. Translating basic science into clinical practice
Chapter: Crohn’s Disease: Clinical Course and Complications
Page 235 - 251Sands BEEditors: S.R. Targan, F. Shanahan, L.C. Karp.Wiley-Blackwell, Hoboken, NJ2010

Abstracts/Posters

An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele
Forcione DG, Sands B, Isselbacher KJ, Rustgi A, Podolsky DK, Pillai S, Proc Natl Acad Sci U S A, 1/1/1996

Lectures

Postoperative Recurrence: How Do I Minimize Risk?
Miami, FL - 1/1/2014
Treating Ulcerative Colitis with New Biologic Therapies
San Diego, CA - 1/1/2013
Biologics 101
San Diego, CA - 1/1/2013

Other

The Facts About Inflammatory Bowel Diseases
Sands BE, Crohn’s and Colitis Foundation of America
1/1/2011
Quality of Care in IBD
Sands BE, Siegel CA, Kappelman M, Crohn’s and Colitis Foundation’s Clinical and Research Conference
Hollywood, FL - 1/10/2010
Biologics in IBD: Do the Risks Outweigh the Benefits?
Sands BE, AGA Perspectives
1/1/2010

Press Mentions

Mount Sinai’s Jean-Frédéric Colombel, MD, to Deliver the 31st Anatomy Lesson in Amsterdam, Highlighting Global Efforts to Prevent and Cure Crohn’s DiseaseNovember 10th, 2025
Mount Sinai’s Dr. Jean-Frédéric Colombel to Present 31st Anatomy Lesson in Amsterdam, Showcasing Global Advances in Crohn’s Disease Prevention and CureNovember 10th, 2025
Meet the Leaders of the Top 5 GI Hospitals in the USOctober 14th, 2025

Grant Support

Translating Scientific Evidence into Practice using Digital Medicine and Electronic Patient Reported OutcomesICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2020–2025